J 2026

Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

CERBONE, Linda; Giandomenico ROVIELLO; Fabio CALABRO; Tarek TAHA; Enrique GRANDE et al.

Základní údaje

Originální název

Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

Autoři

CERBONE, Linda; Giandomenico ROVIELLO; Fabio CALABRO; Tarek TAHA; Enrique GRANDE; Kirstin BINZ; Ravindran KANESVARAN; Alina PIRSTUK; Ondrej FIALA; Javier MOLINA-CERRILLO; Teresa ALONSO-GORDOA; Alessandro RIZZO; Renate PICHLER; Zin W MYINT; Alexandr POPRACH; Gaetano FACCHINI; Bohuslav MELICHAR; Hana STUDENTOVA; Franco MORELLI; Tomas BUCHLER; Alessia MENNITTO; Deniz TURAL; Luigi FORMISANO; Inmaculada OREJANA; Martina CATALANO; Sebastiano BUTI; Fernando Sabino Marques MONTEIRO; Andrey SOARES; Shilpa GUPTA; Francesco MASSARI a Matteo SANTONI

Vydání

Frontiers in immunology, LAUSANNE, Frontiers Media S.A. 2026, 1664-3224

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.900 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

EID Scopus

Klíčová slova anglicky

avelumab; immunotherapy; liver metastases; NCT05290038; pembrolizumab; urothelial carcinoma

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 7. 4. 2026 12:25, Mgr. Tereza Miškechová

Anotace

V originále

Background: Over the past decade, the treatment landscape for metastatic urothelial carcinoma (mUC) has improved significantly with the introduction of immunotherapy, targeted agents, and antibody-drug conjugates. The median overall survival (mOS) reached 36.7 months in cisplatin-eligible and 25.6 months in cisplatin-ineligible patients in the first-line setting and over 10 months post-platinum failure. However, liver metastases remain a known poor prognostic factor. Methods: We conducted a retrospective analysis of mUC patients treated at 79 global institutions. Two cohorts were defined: cohort 1 included patients who progressed after platinum-based therapy and received pembrolizumab, and cohort 2 included patients who received avelumab as maintenance therapy. Treatments were administered between 1 January 2016 and 31 October 2024. Results: Cohort 1 (n = 1,341) had an mOS of 17.5 months. Patients without liver metastases had significantly longer OS than those with liver involvement (20.1 vs. 9.4 months, p <0.001). Among patients with liver metastases, OS was 11.8 months in males vs. 5.8 months in females (p = 0.066). OS was longer in those with BMI >= 25 kg/m & sup2; (14.1 vs. 8.1 months, p = 0.028) and better ECOG-PS (ECOG 0: 17.0 months; ECOG 1: 9.8; ECOG >= 2: 3.1; p <0.001). Cohort 2 (n = 291) had an mOS of 25.8 months. Again, OS was longer in patients without liver metastases (27.0 vs. 16.4 months, p <0.001). Among those with liver involvement, OS was 14.7 months in males and 20.0 months in females (p = 0.310). Patients with BMI >= 25 had non-reached OS versus 17.1 months in those with lower BMI (p <0.001). ECOG-PS remained a strong prognostic factor (NR for ECOG 0; 14.7 months for ECOG 1; 4.6 months for ECOG >= 2, p <0.001). Conclusion: Liver metastases are associated with significantly reduced survival in patients with mUC receiving immunotherapy. However, both pembrolizumab and avelumab demonstrated improved outcomes compared with historical chemotherapy data. These findings underscore the need for personalized treatment strategies in high-risk subgroups.